Press release

Results for the nine-month period ended September 30, 2010

- **Published revenue falls (€1,429m, i.e. 5.4%) arising from disposals**
- **Published current operating profit falls (excluding the effect of the professional tax reform)**
- **Stability of operating profit (excluding the effect of the net capital gain on disposal of Medical Analysis France of €31.2m)**
- **Ongoing development and improvement of care offer (investments of €95.3m over the nine-month period)**

Paris, October 28, 2010

➢ **Revenues for the nine months ended September 30, 2010** were down 5.4% based on published figures, mainly as a result of the disposals made in December 2009 and February 2010 as part of the strategy to refocus our activities. Like-for-like, the figures show positive organic growth of 3.2% for the period, mainly thanks to 2 additional working days.

➢ **Current operating profit** was up 5.2% based on published figures, i.e. an increase of €4m, mainly due to the professional tax reform and breaks down as follows:

+ €1m thanks to a rise in revenues (+3.2% organic growth) and continuing efforts to control costs in order to limit the impact of a restrictive tariff policy, which does not offset rising operating costs;

+ €16m due to the professional tax reform;

- €13m arising from changes in the scope of consolidation (including €3m from property refinancing in 2009)

€m	**September 30, 2010**	**Change**	September 30, 2009
Revenue	**1,428.7**	**-5.4%**	1,510.7
EBITDA	**167.5**	**+0.8%**	166.2
Current operating profit	**80.6**	**+5.2%**	76.6
As % of revenue	***5.6%***	***+0.5 point***	*5.1%*
Operating profit *	**102.4**	**+€29.2m**	73.2
Group share of net profit	**44.9**	**+€31.0m**	13.9
Net earnings per share (€)	**0.80**	**+€0.55**	0.25

** Including about €31.2m in capital gains arising on the sale of the medical analysis business in February 2010*

Revenue: lower published revenue and organic growth

Consolidated revenue for the nine-month period ended September 30, 2010 amounted to €1,428.7m, down from €1,510.7m for the same period in 2009

€m -	**Sep. 30, 2010**	**Sep. 30, 2009**	***Change 2010/2009***	**Q3 2010**	**Q3 2009**	***Change 2010/2009***
Ile de France (Paris region)	*555.6*	*533.6*	*+4.1%*	*161.5*	*157.7*	*+2.4%*
Rhône Alpes	*228.5*	*216.3*	*+5.6%*	*68.6*	*67.0*	*+2.4%*
Nord	*148.6*	*148.0*	*+0.4%*	*46.7*	*45.4*	*+2.9%*
Provence Alpes Côte d'Azur	*167.3*	*163.3*	*+2.4%*	*48.9*	*50.0*	*-2.2%*
Burgundy	*77.6*	*76.2*	*+1.8%*	*24.1*	*23.5*	*+2.6%*
Other regions	*242.5*	*235.6*	*+2.9%*	*73.7*	*74.1*	*-0.5%*
Other activities (1)	*8.6*	*137.7*	*-93.8%*	*1.2*	*39.9*	*-97.0%*
Published revenue	**1,428.7**	**1,510.7**	**-5.4%**	**424.7**	**457.6**	***-7.2%***
o/w: - Organic	**1,426.0**	**1,381.2**	**+3.2%**	**424.7**	418.7	**+1.4%**
o/w organic France	***1,408.7***	***1,364.8***	***+3.2%***	***420.1***	*414.0*	***+1.5%***
o/w organic Italy	***17.3***	***16.4***	***+5.5%***	***4.6***	*4.7*	***-2.1%***
- Changes in scope	**2.7**	**129.5**	**-**	**0.0**	38.9	**-**

(1) "Other activities" includes non-strategic businesses whose assets have been sold

Based on published figures, Hospital Care France recorded a 3.4% decline in revenue during the first nine months of 2010. Adjusted to reflect changes in the scope of consolidation, this segment recorded organic growth of +3.2%, including:

- a +0.2% price effect,
- a +3.0% volume/mix effect (with two additional working days for around 1.0%).

The lower organic growth in France between Q1 2010 (+4.8% - see press release dated April 22, 2010), Q2 2010 (+3.1% - see press release dated August 2, 2010) and Q3 2010 (+1.4%), is related to the implementation from March 1, 2010 of the new V12 nomenclature, which, aside from freezing the tariffs for acute care, has changed the remuneration rules for certain fixed-price procedures and reimbursements of medicine and medical procedures.

In the nine months ended September 30, 2010, the volume of acute care patient stays at the Group's hospitals increased 0.7% to 660,000. This growth was primarily attributable to the increase in surgery (+1.2%, 337,000 patient stays), particularly ophthalmological, orthopedic and visceral surgery. Moreover, medicine grew slightly (+0.2%, 247,000 patient stays) while obstetrics was stable (with 75,000 patient stays). As part of public-service healthcare initiatives managed by the Group, the number of emergencies rose by 2.9% in the first nine months, that is, 287,000 patient visits in the Group's establishments.

In Q3 2010, three events regarding acute care had a marked effect on the Group:

- on August 2, 2010: first intake of patients from Hôpital Privé de L'Estuaire (Le Havre), result of the merger of the clinics François 1er and Petit Comoulins, a new establishment of more than 400 beds and places (in-patient + out-patient) providing a comprehensive range of health-care services, with, in particular, an emergency service, 16 operating

theatres, a maternity unit, 30 dialysis machines, an intensive cardiological care unit, a home hospital care service,
- on August 14, 2010: inauguration of new buildings at the Jeanne d'Arc clinic, located on the site of the Giennois Health Care Unit, a clinic of 121 beds and places (in-patient + out-patient) equipped with state-of-the-art surgical, obstetric, advanced treatment and diagnostic facilities, with 8 operating theatres,
- in September, in Arras, the transfer of maternity and surgery services from the Sainte Catherine clinic to the Bon Secours clinic, to create Hôpital Privé Arras les Bonnettes, a multidisciplinary hospital with 284 beds, 90 doctors and surgeons, and 228 paramedical carers.

As regards the Group's medium-term patient stay activities, volumes increased by 2.8% (with a total of 24,400 patient stays) in the first nine months; this was thanks to higher occupancy rates, but also the increased impact of the extensions at the Bazincourt and Bois d'Amour sub-acute care and rehabilitation sites in the Paris region, the founding of a short-term mental healthcare unit in Belle Allée (near Orleans) and the acquisition of Clinique de Saint Victor in Saint-Etienne.

In France, changes in the scope of consolidation mainly relate to the sale of the Home Care business as of December 31, 2009 and the sale of the Medical Analysis business as of February 2, 2010.

Following the sale of the portion of the Group's Medical Analysis business based in Italy, effective as of December 31, 2009, the entirety of the Group's organic revenue in Italy is now generated by Ospedale Madonna del Popolo in Omegna. This establishment's activity increased strongly in the first nine months of 2010, by +5.5%.

Results – Current operating profit (€80.6m) rose +5.2%, but it includes the effect of the two additional working days at the end of September and the effect of the professional tax reform. In a very restrictive tariff environment, the Group must continue developing its efficiency improvement programs for its establishments: e.g. optimizing procurement, updating internal organizations and sharing best practises, controlling overheads. Private hospitals will increasingly face the need to adapt to changes in their environment and changing healthcare needs.

Total operating profit of €102.4m includes the capital gain of €31.2m recorded in the first quarter of 2010 following the disposal of the Medical Analysis division in France and the impact of the professional tax reform of €16.0m (including €12.7m reclassification to "Corporate income tax" according to IAS12).

The Group share of net profit thus increased from €13.9m as of September 30, 2009 to €44.9m as of September 30, 2010. Stripping out the impact of the disposal of the Medical Analysis division in France, net profit would have been €14.8m.

Net debt – Net financial debt per IFRS was €932.7m at end-September 2010 compared to €885.8m at end-December 2009 and €1,047.9m at September 30, 2009. The Net debt / EBITDA ratio was 3.91 at September 30, 2010.

Acquisition of Hôpital privé de Marne-la-Vallée - At the beginning of October, the Group announced (see press release of October 4, 2010) the acquisition of Hôpital privé de Marne-la-Vallée, which is situated in Bry-sur-Marne (Val de Marne). This takeover will have an effect on Générale de Santé's Q4 2010 consolidated accounts.

With 200 beds and places (in-patient + out-patient), 11 operating theatres and 22 consultation rooms and a total floor space of 18,000 m², it is one of the most up-to-date healthcare institution in east Paris. It was built to serve the population of the Marne-la-Vallée basin (300,000 inhabitants).
This acquisition brings to six the number of healthcare institutions owned by the Group in east Paris.
Once the regulatory authorities have given their approval, this strong presence will give Générale de Santé a real chance to restructure and modernise its care offer in this part of the Paris region.

Dates for your diary:

Publication of full-year 2010 results: February 10, 2011

Générale de Santé is listed on Eurolist by Euronext Paris (formerly known as the Premier Marché) since June 2001. Its shares are eligible for the deferred settlement service. As the leading Group in the private hospital care sector in France, Générale de Santé has 27,000 employees in 110 hospitals and clinics. With 5,000 physicians at December 31, 2009, it represents the leading independent medical community in France. Générale de Santé provides a complete range of patient care services spanning: acute care, oncology, subacute care and rehabilitation, mental health and homecare. Générale de Santé develops an original healthcare offering, combining medical excellence, organizational efficiency and a human touch; it provides an all-in-one service with an individually-adapted patient support package, before, during and after hospitalization, taking into consideration all of its patients' needs; it takes part in public-service healthcare initiatives and forms part of the nationwide healthcare chain in France.

ISIN code and Euronext Paris: FR0000044471
Website: www.generale-de-sante.fr

Investor Relations/Analysts:
Emmanuel de Geuser
Tél. + 33 (0)1 53 23 14 89
e.degeuser@gsante.fr

Press Relations:
Gérard Benedetti
Tél. + 33 (0) 1 53 23 14 47
g.benedetti@gsante.fr

STATEMENT OF COMPREHENSIVE INCOME (unaudited)

(in million euros)	Period ended 30 september 2009	Period ended 30 september 2010
TURNOVER	**1 510.7**	**1 428.7**
Personnel expenses and profit sharing	(687.6)	(659.4)
Purchased consumables	(290.7)	(269.5)
Other operating income and expenses	(186.7)	(171.0)
Taxes and duties	(78.9)	(61.6)
Rents	(100.6)	(99.7)
EBITDA	**166.2**	**167.5**
Depreciation	(89.6)	(86.9)
Current operating profit	**76.6**	**80.6**
Restructuring costs	(6.3)	(10.8)
Result of the management of real estate and financial assets	2.9	32.6
Impairment of goodwill	--	--
Other non current income and expenses	**(3.4)**	**21.8**
Operating profit	**73.2**	**102.4**
Gross interest expenses	(42.4)	(34.8)
Income from cash and cash equivalents	0.5	0.6
Net interest expenses	**(41.9)**	**(34.2)**
Other financial income	0.6	0.6
Other financial expenses	(3.9)	(3.7)
Other financial income and expenses	**(3.3)**	**(3.1)**
Corporate income tax	(11.1)	(16.5)
Share of net profit of associates	--	--
NET PROFIT FOR THE PERIOD	**16.9**	**48.6**
Revenues and expenses recognised directly as equity		
- Retirement commitments	--	--
- Change in fair value of hedging financial instruments	(6.0)	0.5
- Translation differential	--	--
- Income tax on other comprehensive income	2.1	(0.2)
Résults recognised directly as equity	**(3.9)**	**0.3**
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	**13.0**	**48.9**

PROFIT ATTRIBUTABLE TO (in million euros)	Period ended 30 september 2009	Period ended 30 september 2010
Group's share of net earnings	13.9	44.9
Non-controlling interests	3.0	3.7
NET PROFIT FOR THE PERIOD	**16.9**	**48.6**

TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO (in millions euros)	Period ended 30 september 2009	Period ended 30 september 2010
Group's comprehensive income for the period	10.0	45.2
Non-controlling interests	3.0	3.7
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	**13.0**	**48.9**

CONSOLIDATED BALANCE SHEET – ASSETS

(in million euros)	**12-31-2009**	**At september 30, 2010 (unaudited)**
Goodwill	627.9	626.8
Other intangible fixed assets	19.2	25.1
Tangible fixed assets	915.6	923.8
Investments in associates	0.1	0.1
Other long-term investments	28.1	29.6
Deferred tax assets	50.5	51.8
NON CURRENT ASSETS	**1,641.4**	**1,657.2**
Inventories	32.8	33.4
Trade and other receivables	130.0	141.3
Other current assets	139.9	153.0
Current tax assets	2.0	8.2
Current financial assets	13.2	4.4
Cash and cash equivalents	---	---
Assets held for sale	56.2	4.2
CURRENT ASSETS	**374.1**	**344.5**
TOTAL ASSETS	**2,015.5**	**2,001.7**

CONSOLIDATED BALANCE SHEET – LIABILITIES

(in million euros)	**12-31-2009**	**At september 30, 2010 (unaudited)**
Share capital	42.2	42.2
Additional paid-in capital	62.5	62.5
Consolidated reserves	320.0	295.2
Group's share of net profit	42.4	44.9
Group's share of equity	**467.1**	**444.8**
Non-controlling interests	10.0	11.9
TOTAL SHAREHOLDERS' EQUITY	**477.1**	**456.7**
Borrowings and financial debts	702.4	784.1
Provisions for retirement and other employee benefits	29.7	32.0
Non-current provisions	37.3	33.6
Other long term liabilities	35.4	36.0
Deferred tax liabilities	81.3	79.7
NON CURRENT LIABILITIES	**886.1**	**965.4**
Current provisions	13.8	12.6
Accounts payable	124.1	127.6
Other current liabilities	296.2	296.5
Tax liabilities due	0.6	---
Short-term borrowings	154.7	88.1
Bank overdraft	5.1	50.6
Liabilities related to assets held for sale	57.8	4.2
CURRENT LIABILITIES	**652.3**	**579.6**
TOTAL EQUITY AND LIABILITIES	**2,015.5**	**2,001.7**

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

(in million euros)	SHARE CAPITAL	ADDITIONAL PAID IN CAPITAL	RESERVES	RESULTS RECOGNISED DIRECTLY AS EQUITY	TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	GROUP'S SHARE OF EQUITY	Non-controlling interests	SHAREHOLDERS' EQUITY
Shareholders' equity at 31 december 2008	**42.2**	**61.5**	**329.1**	**(19.6)**	**87.2**	**500.4**	**10.0**	**510.4**
Capital increase (including net fees)......................................	--	1.0	--	--	--	1.0	--	1.0
Treasury shares..	--	--	(9.4)	--	--	(9.4)	--	(9.4)
Stocks options and free share..	--	--	2.6	--	--	2.6	--	2.6
Prior year appropriation of earnings.......................................	--	--	87.2	--	(87.2)	--	--	--
Distribution of dividends	--	--	(69.3)	--	--	(69.3)	(1.8)	(71.1)
Change in consolidation scope	--	--	--	--	--	--	(1.1)	(1.1)
Total comprehensive income for the period...........................	--	--	--	(0.6)	42.4	41.8	2.9	44.7
Shareholders' equity at 31 december 2009	**42.2**	**62.5**	**340.2**	**(20.2)**	**42.4**	**467.1**	**10.0**	**477.1**
Capital increase (including net fees)......................................	--	--	--	--	--	--	--	--
Treasury shares..	--	--	--	--	--	--	--	--
Stocks options and free share..	--	--	2.5	--	--	2.5	--	2.5
Prior year appropriation of earnings.......................................	--	--	42.4	--	(42.4)	--	--	--
Distribution of dividends	--	--	(69.9)	--	--	(69.9)	(1.8)	(71.7)
Change in consolidation scope	--	--	(0.1)	--	--	(0.1)	--	(0.1)
Total comprehensive income for the period...........................	--	--	--	0.3	44.9	45.2	3.7	48.9
Shareholders' equity at 30 september 2010 (unaudited)	**42.2**	**62.5**	**315.1**	**(19.9)**	**44.9**	**444.8**	**11.9**	**456.7**

REVENUES AND EXPENSES RECOGNISED DIRECTLY AS EQUITY

(in million euros)	12-31-2008	Revenues and expenses 2009	12-31-2009	Revenues and expenses at september 30, 2009	At september 30, 2010 (unaudited)
Translation differential	**(0.3)**	--	**(0.3)**	--	**(0.3)**
Retirement commitments	**(5.1)**	1.1	**(4.0)**	--	**(4.0)**
Fair value of hedging financial instruments	**(14.2)**	(1.7)	**(15.9)**	0.3	**(15.6)**
Results recognised directly as equity (Group's share)	**(19.6)**	**(0.6)**	**(20.2)**	**0.3**	**(19.9)**

CONSOLIDATED CASH FLOW STATEMENT (unaudited)

(in million euros)	Period ended 30 september 2009	Period ended 30 september 2010
Total net consolidated profit	16.9	48.6
Depreciation	89.6	86.9
Other non current income and expenses	3.4	(21.8)
Share of net profit of associates	--	--
Other financial income and expenses	3.3	3.1
Net interest expenses	41.9	34.2
Corporate income tax	11.1	16.5
EBITDA	**166.2**	**167.5**
Non cash items including provisions and reversals (transactions with no cash effect)	(5.3)	--
Other income and expenses paid	(6.7)	(9.1)
Changes in other long term assets and liabilities	(1.2)	1.7
Cash flow before net interest expenses & taxes	**153.0**	**160.1**
Corporate income tax paid	(19.3)	(26.9)
Change in working capital requirements	(43.3)	(21.4)
NET CASH FROM OPERATING ACTIVITIES : (A)	**90.4**	**111.8**
Purchase of property, plant & equipment and intangible assets	(84.2)	(88.6)
Proceeds from sale of tangible and intangible assets	5.6	--
Purchase of financial assets	(23.8)	(3.3)
Proceeds from the disposal of financial assets	6.9	55.8
Dividends from non consolidated companies	0.5	0.4
NET CASH USED FOR INVESTING ACTIVITIES : (B)	**(95.0)**	**(35.7)**
Capital increase: (a)	1.0	--
Capital increase performed by subsidiaries subscribed to by third parties (b)	--	--
Exceptional distribution of additional paid-in capital (c)	--	--
Dividends paid to GDS shareholders: (d)	(69.3)	(69.9)
Dividends paid to minority interests of consolidated companies: (e)	(1.8)	(1.8)
Net interest expense paid : (f)	(41.9)	(34.2)
Debt issue costs : (g)	--	--
Cash flow before repayment of borrowings: (h) = (A+B + a + b + c + d + e + f + g)	**(116.6)**	**(29.8)**
Increase in borrowings : (i)	139.0	120.8
Repayment of borrowings : (j)	(51.7)	(149.5)
NET CASH USED FOR FINANCING ACTIVITIES: (C) = a + b + c + d + e + f + g + i + j	**(24.7)**	**(134.6)**
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS: (A + B + C)	**(29.3)**	**(58.5)**
Reclassification of the cash of the assets held for sale		13.0
Cash and cash equivalents at beginning of period	(6.8)	(5.1)
Cash and cash equivalents at end of period	(36.1)	(50.6)
Net indebtedness at beginning of period	**913.0**	**885.8**
Cash flow before repayment of borrowings: (h)	116.6	29.8
Capitalization of financial leases	23.2	6.7
Loan issue charges fixed assets	2.6	2.6
Assets held for sale	(1.8)	(0.6)
Fair value of financial hedging instruments	3.9	(0.3)
Change in scope of consolidation and other	(9.6)	8.7
Net indebtedness at end of period	**1,047.9**	**932.7**